368 related articles for article (PubMed ID: 36874402)
21. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].
Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157
[No Abstract] [Full Text] [Related]
22. Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors.
Prasongtanakij S; Preedagasamzin S; Jittorntrum B; Anurathapan U; Puavilai T; Niparuck P; Chantrathammachart P; Piyajaroenkij T; Uaesoontrachoon K; Uchibori R; Ozawa K; Ohmine K; Hongeng S
Eur J Haematol; 2024 Feb; 112(2):248-256. PubMed ID: 37222081
[TBL] [Abstract][Full Text] [Related]
23. BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S; Chandrakasan S; Leung K; Bryson E; Deeb L; Kaufman JL; Worthington-White D; Alazraki A; Schecter JM; Madduri D; Jackson CC; Zudaire E; Taraseviciute-Morris A; Babich A; Nesheiwat T; Vogel M; Lendvai N; Pacaud L; Williams KM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37137553
[TBL] [Abstract][Full Text] [Related]
24. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
25. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
Front Immunol; 2021; 12():609421. PubMed ID: 33767695
[TBL] [Abstract][Full Text] [Related]
26. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
[No Abstract] [Full Text] [Related]
28. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
29. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
30. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
31. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.
Dhakal B; Hari PN; Usmani SZ; Hamadani M
Bone Marrow Transplant; 2021 Jan; 56(1):9-19. PubMed ID: 32770147
[TBL] [Abstract][Full Text] [Related]
33. BCMA CAR-T cells in multiple myeloma-ready for take-off?
Scheller L; Tebuka E; Rambau PF; Einsele H; Hudecek M; Prommersberger SR; Danhof S
Leuk Lymphoma; 2024 Feb; 65(2):143-157. PubMed ID: 37997705
[TBL] [Abstract][Full Text] [Related]
34. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
Zhang X; Zhang H; Lan H; Wu J; Xiao Y
Front Immunol; 2023; 14():1101495. PubMed ID: 36891310
[TBL] [Abstract][Full Text] [Related]
35. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
[TBL] [Abstract][Full Text] [Related]
36. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Sun F; Cheng Y; Wanchai V; Guo W; Mery D; Xu H; Gai D; Siegel E; Bailey C; Ashby C; Al Hadidi S; Schinke C; Thanendrarajan S; Ma Y; Yi Q; Orlowski RZ; Zangari M; van Rhee F; Janz S; Bishop G; Tricot G; Shaughnessy JD; Zhan F
Nat Commun; 2024 Jan; 15(1):615. PubMed ID: 38242888
[TBL] [Abstract][Full Text] [Related]
37. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma.
Xu J; Wang Q; Xu H; Gu C; Jiang L; Wang J; Wang D; Xu B; Mao X; Wang J; Wang Z; Xiao Y; Zhang Y; Li C; Zhou J
J Hematol Oncol; 2018 Oct; 11(1):128. PubMed ID: 30348186
[TBL] [Abstract][Full Text] [Related]
38. PD1
Mishra AK; Schmidt TM; Martell EB; Chen AS; Dogru RE; Hematti P; Callander NS
Transplant Cell Ther; 2024 Feb; 30(2):191-202. PubMed ID: 37967650
[TBL] [Abstract][Full Text] [Related]
39. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.
Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
[TBL] [Abstract][Full Text] [Related]
40. Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
Works M; Soni N; Hauskins C; Sierra C; Baturevych A; Jones JC; Curtis W; Carlson P; Johnstone TG; Kugler D; Hause RJ; Jiang Y; Wimberly L; Clouser CR; Jessup HK; Sather B; Salmon RA; Ports MO
Mol Cancer Ther; 2019 Dec; 18(12):2246-2257. PubMed ID: 31395689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
